Kelly R Peck1,2,3, Taylor A Ochalek1,3, Joanna M Streck1,3, Gary J Badger4, Stacey C Sigmon1,2,3. 1. Vermont Center on Behavior and Health, University of Vermont, Burlington, Vermont, USA. 2. Departments of Psychiatry, Burlington, Vermont, USA. 3. Psychological Science, Burlington, Vermont, USA. 4. Medical Biostatistics, University of Vermont, Burlington, Vermont, USA.
Abstract
OBJECTIVE: Chronic non-cancer pain (CNCP) is prevalent among individuals with opioid use disorder (OUD). However, the impact of CNCP on buprenorphine treatment outcomes is largely unknown. In this secondary analysis, we examined treatment outcomes among individuals with and without CNCP who received a low-barrier buprenorphine maintenance regimen during waitlist delays to more comprehensive opioid treatment. METHODS: Participants were 28 adults with OUD who received 12 weeks of buprenorphine treatment involving bimonthly clinic visits, computerized medication dispensing, and phone-based monitoring. At intake and monthly follow-up assessments, participants completed the Brief Pain Inventory, Beck Anxiety Inventory, Beck Depression Inventory (BDI-II), Brief Symptom Inventory (BSI), Addiction Severity Index, and staff-observed urinalysis. RESULTS: Participants with CNCP (n = 10) achieved comparable rates of illicit opioid abstinence as those without CNCP (n = 18) at weeks 4 (90% vs 94%), 8 (80% vs 83%), and 12 (70% vs 67%) (P = 0.99). Study retention was also similar, with 90% and 83% of participants with and without CNCP completing the 12-week study, respectively (P = 0.99). Furthermore, individuals with CNCP demonstrated significant improvements on the BDI-II and Global Severity Index subscale of the BSI (P < 0.05). However, those with CNCP reported more severe medical problems and smaller reductions in legal problems relative to those without CNCP (P = 0.03). CONCLUSIONS: Despite research suggesting that chronic pain may influence OUD treatment outcomes, participants with and without CNCP achieved similar rates of treatment retention and significant reductions in illicit opioid use and psychiatric symptomatology during low-barrier buprenorphine treatment.
OBJECTIVE: Chronic non-cancer pain (CNCP) is prevalent among individuals with opioid use disorder (OUD). However, the impact of CNCP on buprenorphine treatment outcomes is largely unknown. In this secondary analysis, we examined treatment outcomes among individuals with and without CNCP who received a low-barrier buprenorphine maintenance regimen during waitlist delays to more comprehensive opioid treatment. METHODS: Participants were 28 adults with OUD who received 12 weeks of buprenorphine treatment involving bimonthly clinic visits, computerized medication dispensing, and phone-based monitoring. At intake and monthly follow-up assessments, participants completed the Brief Pain Inventory, Beck Anxiety Inventory, Beck Depression Inventory (BDI-II), Brief Symptom Inventory (BSI), Addiction Severity Index, and staff-observed urinalysis. RESULTS: Participants with CNCP (n = 10) achieved comparable rates of illicit opioid abstinence as those without CNCP (n = 18) at weeks 4 (90% vs 94%), 8 (80% vs 83%), and 12 (70% vs 67%) (P = 0.99). Study retention was also similar, with 90% and 83% of participants with and without CNCP completing the 12-week study, respectively (P = 0.99). Furthermore, individuals with CNCP demonstrated significant improvements on the BDI-II and Global Severity Index subscale of the BSI (P < 0.05). However, those with CNCP reported more severe medical problems and smaller reductions in legal problems relative to those without CNCP (P = 0.03). CONCLUSIONS: Despite research suggesting that chronic pain may influence OUD treatment outcomes, participants with and without CNCP achieved similar rates of treatment retention and significant reductions in illicit opioid use and psychiatric symptomatology during low-barrier buprenorphine treatment.
Authors: Declan T Barry; Matthew J Bernard; Mark Beitel; Brent A Moore; Robert D Kerns; Richard S Schottenfeld Journal: J Addict Med Date: 2008-06 Impact factor: 3.702
Authors: Lara Dhingra; David C Perlman; Carmen Masson; Jack Chen; Courtney McKnight; Ashly E Jordan; Thomas Wasser; Russell K Portenoy; Martin D Cheatle Journal: Drug Alcohol Depend Date: 2015-02-17 Impact factor: 4.492
Authors: Jodie A Trafton; Elizabeth M Oliva; Doyanne A Horst; Jared D Minkel; Keith Humphreys Journal: Drug Alcohol Depend Date: 2004-01-07 Impact factor: 4.492
Authors: Declan T Barry; Christopher J Cutter; Mark Beitel; Robert D Kerns; Christopher Liong; Richard S Schottenfeld Journal: J Clin Psychiatry Date: 2016-10 Impact factor: 4.384
Authors: Declan T Barry; Mark Beitel; Brian Garnet; Dipa Joshi; Andrew Rosenblum; Richard S Schottenfeld Journal: J Clin Psychiatry Date: 2009-07-14 Impact factor: 4.384
Authors: Brittany B Dennis; Monica Bawor; Leen Naji; Carol K Chan; Jaymie Varenbut; James Paul; Michael Varenbut; Jeff Daiter; Carolyn Plater; Guillaume Pare; David C Marsh; Andrew Worster; Dipika Desai; Lehana Thabane; Zainab Samaan Journal: Subst Abuse Date: 2015-09-10